Palvella Therapeutics (PVLA) Other Non Operating Income (2014 - 2026)
Palvella Therapeutics' (PVLA) quarterly Other Non Operating Income came in at -$32000.0 in Q1 2026, up 57.33% year-on-year from -$20339.0 in Q1 2025, and up 73.11% on a QoQ basis from -$119000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Other Non Operating Income (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Other Non Operating Income data on file, last reported at -$32000.0 in Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 57.33% year-over-year to -$32000.0 in Q1 2026; TTM through Mar 2026 was $328000.0, a 12.06% decrease from a year earlier, with the FY2025 full-year figure at -$394000.0, changed N/A from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$32000.0, up from -$119000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for PVLA reached as high as $723000.0 in Q3 2022 and fell as low as -$325000.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged $156352.9 across 5 years, with a median of -$20000.0 in 2024.
- On a YoY basis, Other Non Operating Income climbed as much as 776.56% in 2025 and fell as far as 310.0% in 2025.
- Year by year, Other Non Operating Income stood at -$325000.0 in 2022, then jumped by 230.46% to $424000.0 in 2023, then decreased by 4.72% to $404000.0 in 2024, then tumbled by 129.46% to -$119000.0 in 2025, then surged by 73.11% to -$32000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$32000.0 in Q1 2026, -$119000.0 in Q4 2025, and -$82000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Dec 31, 2025 | -119,000.00 |
| Sep 30, 2025 | -82,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | -75,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Sep 30, 2024 | -20,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | 424,000.00 |
| Sep 30, 2023 | 506,000.00 |
| Jun 30, 2023 | -161,000.00 |
| Mar 31, 2023 | -57,000.00 |
| Dec 31, 2022 | -325,000.00 |
| Sep 30, 2022 | 723,000.00 |
| Jun 30, 2022 | 676,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 378,000.00 |
| Sep 30, 2021 | 678,000.00 |
| Jun 30, 2021 | 464,000.00 |